156 related articles for article (PubMed ID: 33361404)
1. Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma.
Nakamura M; Nagase K; Yoshimitsu M; Magara T; Nojiri Y; Kato H; Kobayashi T; Teramoto Y; Yasuda M; Wada H; Ozawa T; Umemori Y; Ogata D; Morita A
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361404
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
Lipson EJ; Vincent JG; Loyo M; Kagohara LT; Luber BS; Wang H; Xu H; Nayar SK; Wang TS; Sidransky D; Anders RA; Topalian SL; Taube JM
Cancer Immunol Res; 2013 Jul; 1(1):54-63. PubMed ID: 24416729
[TBL] [Abstract][Full Text] [Related]
3. MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series.
Ugurel S; Spassova I; Wohlfarth J; Drusio C; Cherouny A; Melior A; Sucker A; Zimmer L; Ritter C; Schadendorf D; Becker JC
Cancer Immunol Immunother; 2019 Jun; 68(6):983-990. PubMed ID: 30993371
[TBL] [Abstract][Full Text] [Related]
4. Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
Bénigni P; Guénolé M; Bonsang B; Marcorelles P; Schick U; Uguen A
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):17-22. PubMed ID: 31343994
[TBL] [Abstract][Full Text] [Related]
5. The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
Guénolé M; Bénigni P; Bourbonne V; Lucia F; Legoupil D; Pradier O; Misery L; Uguen A; Schick U
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2569-2578. PubMed ID: 34115240
[TBL] [Abstract][Full Text] [Related]
6. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
Wehkamp U; Stern S; Krüger S; Weichenthal M; Hauschild A; Röcken C; Egberts F
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1301-1308. PubMed ID: 29744662
[TBL] [Abstract][Full Text] [Related]
8. Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma.
Richter I; Dvorak TJECJBTBJ
J BUON; 2019; 24(5):2155-2160. PubMed ID: 31786889
[TBL] [Abstract][Full Text] [Related]
9. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
[TBL] [Abstract][Full Text] [Related]
10. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy.
Knepper TC; Montesion M; Russell JS; Sokol ES; Frampton GM; Miller VA; Albacker LA; McLeod HL; Eroglu Z; Khushalani NI; Sondak VK; Messina JL; Schell MJ; DeCaprio JA; Tsai KY; Brohl AS
Clin Cancer Res; 2019 Oct; 25(19):5961-5971. PubMed ID: 31399473
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas.
Behr DS; Peitsch WK; Hametner C; Lasitschka F; Houben R; Schönhaar K; Michel J; Dollt C; Goebeler M; Marx A; Goerdt S; Schmieder A
Int J Clin Exp Pathol; 2014; 7(11):7610-21. PubMed ID: 25550797
[TBL] [Abstract][Full Text] [Related]
12. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
[TBL] [Abstract][Full Text] [Related]
13. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
14. The biology and treatment of Merkel cell carcinoma: current understanding and research priorities.
Harms PW; Harms KL; Moore PS; DeCaprio JA; Nghiem P; Wong MKK; Brownell I;
Nat Rev Clin Oncol; 2018 Dec; 15(12):763-776. PubMed ID: 30287935
[TBL] [Abstract][Full Text] [Related]
15. Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.
Feldmeyer L; Hudgens CW; Ray-Lyons G; Nagarajan P; Aung PP; Curry JL; Torres-Cabala CA; Mino B; Rodriguez-Canales J; Reuben A; Chen PL; Ko JS; Billings SD; Bassett RL; Wistuba II; Cooper ZA; Prieto VG; Wargo JA; Tetzlaff MT
Clin Cancer Res; 2016 Nov; 22(22):5553-5563. PubMed ID: 27166398
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
Samimi M
Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Barkdull S; Brownell I
Cancer Biol Ther; 2017 Dec; 18(12):937-939. PubMed ID: 29172995
[TBL] [Abstract][Full Text] [Related]
18. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.
Paulson KG; Iyer JG; Tegeder AR; Thibodeau R; Schelter J; Koba S; Schrama D; Simonson WT; Lemos BD; Byrd DR; Koelle DM; Galloway DA; Leonard JH; Madeleine MM; Argenyi ZB; Disis ML; Becker JC; Cleary MA; Nghiem P
J Clin Oncol; 2011 Apr; 29(12):1539-46. PubMed ID: 21422430
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for Merkel Cell Carcinoma.
Nagase K; Narisawa Y
Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
